Alkermes plc. Finite-Lived Intangible Assets, Net
Alkermes plc. (ALKS) had Finite-Lived Intangible Assets, Net of $815.00 thousand as of 2025-12-31, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-07-28
- 2025-12-31: Finite-Lived Intangible Assets, Net $815.00K.
- 2024-12-31: Finite-Lived Intangible Assets, Net $890.00K.
- 2024-09-30: Finite-Lived Intangible Assets, Net $904.00K.
- 2024-06-30: Finite-Lived Intangible Assets, Net $918.00K.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2025-12-31 | $815.00K 10-Q · filed 2026-07-28 |
| 2024-12-31 | $890.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | $904.00K 10-Q · filed 2024-10-24 |
| 2024-06-30 | $918.00K 10-Q · filed 2024-07-24 |
| 2024-03-31 | $932.00K 10-Q · filed 2024-05-01 |
| 2023-12-31 | $1.99M 10-K · filed 2025-02-12 |
| 2023-09-30 | $10.99M 10-Q · filed 2023-10-25 |
| 2023-06-30 | $19.98M 10-Q · filed 2023-07-26 |
| 2023-03-31 | $28.88M 10-Q · filed 2023-04-26 |
| 2022-12-31 | $37.68M 10-K · filed 2024-02-21 |
| 2022-09-30 | $46.84M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $56.01M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $65.08M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $74.04M 10-K · filed 2023-02-16 |
| 2021-09-30 | $83.66M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $93.27M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $101.78M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $111.19M 10-K · filed 2022-02-16 |
| 2020-09-30 | $121.11M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $131.03M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $140.91M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $150.64M 10-K · filed 2021-02-11 |
| 2019-09-30 | $160.81M 10-Q · filed 2019-10-23 |
| 2019-06-30 | $170.99M 10-Q · filed 2019-07-25 |
| 2019-03-31 | $181.05M 10-Q · filed 2019-04-25 |
| 2018-12-31 | $191.00M 10-K · filed 2020-02-13 |
| 2018-09-30 | $207.43M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $223.85M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $240.10M 10-Q · filed 2018-04-26 |
| 2017-12-31 | $256.17M 10-K · filed 2019-02-15 |
| 2017-09-30 | $271.81M 10-Q · filed 2017-10-26 |
| 2017-06-30 | $287.45M 10-Q · filed 2017-07-27 |
| 2017-03-31 | $302.93M 10-Q · filed 2017-04-27 |
| 2016-12-31 | $318.23M 10-K · filed 2018-02-16 |
| 2016-09-30 | $333.55M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $348.87M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $364.03M 10-Q · filed 2016-04-28 |
| 2015-12-31 | $379.19M 10-K · filed 2017-02-17 |
| 2015-09-30 | $393.39M 10-Q · filed 2015-10-29 |
| 2015-06-30 | $407.60M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $464.19M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $479.41M 10-K · filed 2016-02-25 |
| 2014-09-30 | $494.66M 10-Q · filed 2014-10-29 |
| 2014-06-30 | $509.90M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $524.99M 10-Q · filed 2014-04-30 |
| 2013-12-31 | $537.57M 10-K · filed 2015-02-24 |
| 2013-09-30 | $550.42M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $563.28M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $575.99M 10-KT · filed 2014-02-27 |
| 2012-12-31 | $586.32M 10-Q · filed 2013-01-31 |
| 2012-09-30 | $596.86M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $607.41M 10-Q · filed 2012-07-26 |
| 2012-03-31 | $617.85M 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |